Individualized Neoantigen Vaccine Program

Our first oncology program is an individualized neoantigen-based immunotherapy. For each patient, our individualized immunotherapy starts with a routine clinical biopsy. We intend to deliver the immunotherapy in a community oncology setting where a vast majority of cancer patients are treated.

Untitled design (6)

Off-the-Shelf Neoantigen Vaccine Program

The routine clinical biopsy used to identify individualized patient mutations can also identify patients that have common mutations within their tumor from commercially available genomic panel sequencing. Because these neoantigens are shared, an “off-the-shelf” therapy may be able to treat additional patients across multiple tumor types.